Antifungal Susceptibility and Genotypic Analysis of cyp51A Mutations in Aspergillus fumigatus Isolates in Malaysia

References

• Zhang S, Wang S, Wan Z, Li R, Yu J. the diagnosis of invasive and noninvasive pulmonary aspergillosis by serum and bronchoalveolar lavage fluid galactomannan assay. Biomed Res Int. 2015;2015:943691.
   PubMed Web of Science ®Google Scholar
• Thornton CR. Detection of Invasive Aspergillosis. In: Advances in Applied Microbiology. Vol 70. Academic Press Inc.; 2010:187–216.
   Google Scholar
• Baddley JW. Clinical risk factors for invasive aspergillosis. Med Mycol. 2011;49:S7–S12.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–415.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Hassler A, Groll AH, Bochennek K. Diagnostic approaches for invasive aspergillosis-specific considerations in the pediatric population. Front Microbiol. 2018;9:518.
   PubMed Web of Science ®Google Scholar
• Peter Donnelly J, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71(6):1367–1376.
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, De Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. definitions of invasive fungal infections. Clin Infect Dis. 2002;34(7):7–14.
   PubMedGoogle Scholar
• Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi. 2017;3(4):57.
   Web of Science ®Google Scholar
• Denning DW. Therapeutic Outcome in Invasive Aspergillosis. Clin Infect Dis. 1996;23(3):608–615.
   PubMed Web of Science ®Google Scholar
• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32(3):358–366.
   PubMed Web of Science ®Google Scholar
• Velayuthan RD, Samudi C, Singh HKL, Ng KP, Shankar EM, Denning DW. Estimation of the burden of serious human fungal infections in Malaysia. J Fungi. 2018;4(1):38.
   Web of Science ®Google Scholar
• Ragozzino S, Goldenberger D, Wright P, et al. Distribution of Aspergillus species and prevalence of azole resistance in respiratory samples from Swiss tertiary care hospitals. Open Forum Infect Dis. 2022;9(2):546.
   Web of Science ®Google Scholar
• From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology, World Stroke Organization, Sacks D, Baxter B, Campbell BCV, et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke. 2018;13(6):612–632.
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Marr KA, Anaissie EJ, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect. 2012;65(5):453–464.
   PubMed Web of Science ®Google Scholar
• Barton RC. Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Scientifica (Cairo). 2013;2013:1–29.
   Google Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1–e60.
   PubMed Web of Science ®Google Scholar
• National Antimicrobial Guideline. Ministry of Health Malaysia; 2019. Available from: www.pharmacy.gov.my. Accessed 22, October 2023.
   Google Scholar
• Verweij PE, Lucas JA, Arendrup MC, et al. The one health problem of azole resistance in Aspergillus fumigatus: current insights and future research agenda. Fungal Biol Rev. 2020;34(4):202–214.
   Web of Science ®Google Scholar
• Sen P, Vijay M, Singh S, Hameed S, Vijayaraghavan P. Understanding the environmental drivers of clinical azole resistance in Aspergillus species. Drug Target Insights. 2022;16(1):25–35.
   PubMedGoogle Scholar
• Berkow EL, Lockhart SR, Ostrosky-Zeichner L. Antifungal susceptibility testing: current approaches. Clin Microbiol Rev. 2020;33(3):e00069–19.
   PubMed Web of Science ®Google Scholar
• Bader O, Weig M, Reichard U, et al. Cyp51A-based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany. Antimicrob Agents Chemother. 2013;57(8):3513–3517.
   PubMed Web of Science ®Google Scholar
• Hsu TH, Huang PY, Fan YC, Sun PL. Azole Resistance and cyp51A mutation of Aspergillus fumigatus in a tertiary referral hospital in Taiwan. J Fungi (Basel). 2022;8(9):908.
   PubMedGoogle Scholar
• Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009;15(7):1068–1076.
   PubMed Web of Science ®Google Scholar
• Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Substitutions at Methionine 220 in the 14-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother. 2004;48(7):2747–2750.
   PubMed Web of Science ®Google Scholar
• Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A Point mutation in the 14-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2003;47(3):1120–1224.
   PubMed Web of Science ®Google Scholar
• Krishnan Natesan S, Wu W, Cutright JL, Chandrasekar PH. In vitro–in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in Aspergillus fumigatus. Diagn Microbiol Infect Dis. 2012;74(3):272–277.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother. 2012;67(2):362–366.
   PubMed Web of Science ®Google Scholar
• Tam EWT, Chen JHK, Lau ECL, et al. Misidentification of Aspergillus nomius and Aspergillus tamarii as Aspergillus flavus: characterization by internal transcribed spacer, β-tubulin, and calmodulin gene sequencing, metabolic fingerprinting, and matrix-assisted laser desorption ionization–time of flight mass spectrometry. J Clin Microbiol. 2014;52(4):1153.
   PubMed Web of Science ®Google Scholar
• Alexander BD. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. 3rd ed. Wayne, PA: Clinical and Laboratory Standard Institute; 2017.
   Google Scholar
• Tamura K, Stecher G, Kumar S. MEGA11: molecular evolutionary genetics analysis version 11. Mol Biol Evol. 2021;38(7):3022–3027.
   PubMed Web of Science ®Google Scholar
• Yamazhan T, Aydemir S, Tünger A, Serter D, Gökengin D. In vitro activities of various antimicrobials against Brucella melitensis strains in the Aegean region in Turkey. Med Princ Pract. 2005;14(6):413–416.
   PubMed Web of Science ®Google Scholar
• Procop GW. Clinical and Laboratory Standards Institute. Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi. 2nd ed. Wayne, PA: Clinical and Laboratory Standard Institute; 2020.
   Google Scholar
• Li Y, Wang H, Zhao YP, Xu YC, Hsueh PR. Antifungal susceptibility of clinical isolates of 25 genetically confirmed Aspergillus species collected from Taiwan and mainland China. J Microbiol Immunol Infect. 2020;53(1):125–132.
   PubMedGoogle Scholar
• Procop. Epidemiological Cutoff Values for Antifungal Susceptibility Testing. Clinical and Laboratory Standard Institute (CLSI); 2020. 3rd ed. Wayne, PA: Clinical and Laboratory Standard Institute; 2020.
   Google Scholar
• Yang X, Chen W, Liang T, et al. A 20-Year Antifungal susceptibility surveillance (from 1999 to 2019) for Aspergillus spp. and proposed epidemiological cutoff values for Aspergillus fumigatus and Aspergillus flavus: a study in a tertiary hospital in China. Front Microbiol. 2021;12:680884.
   PubMed Web of Science ®Google Scholar
• Kang Y, Li Q, Yao Y, et al. Epidemiology and azole resistance of clinical isolates of Aspergillus fumigatus from a large tertiary hospital in Ningxia, China. Infect Drug Resist. 2024;17:427–439.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang L, Zhou L, Zhang M, Xu Y. Epidemiology, drug susceptibility, and clinical risk factors in patients with invasive aspergillosis. Front Public Health. 2022;10:835092.
   PubMed Web of Science ®Google Scholar
• Takeda K, Suzuki J, Watanabe A, et al. High detection rate of azole-resistant Aspergillus fumigatus after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance. Med Mycol. 2021;59(4):327–334.
   PubMed Web of Science ®Google Scholar
• Moin S, Farooqi J, Jabeen K, Laiq S, Zafar A. Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan. Antimicrob Resist Infect Control. 2020;9(1):62.
   PubMed Web of Science ®Google Scholar
• Cho SY, Lee DG, Kim WB, et al. Epidemiology and antifungal susceptibility profile of aspergillus species: comparison between environmental and clinical isolates from patients with hematologic malignancies. J Clin Microbiol. 2019;57(7).
   PubMed Web of Science ®Google Scholar
• Moglad E, Saeed S, Saeed H, et al. Molecular characterization and antifungal susceptibility of aspergillus spp. among patients with underlying lung diseases. Trop Med Infect Dis. 2022;7(10):274.
   PubMedGoogle Scholar
• Lestrade PP, Bentvelsen RG, Schauwvlieghe AFAD, et al. Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study. Clin Infect Dis. 2019;68(9):1463–1471.
   PubMed Web of Science ®Google Scholar
• Guegan H, Prat E, Robert-Gangneux F, Gangneux JP. Azole resistance in Aspergillus fumigatus: a five-year follow up experience in a tertiary hospital with a special focus on cystic fibrosis. Front Cell Infect Microbiol. 2021;10:613774.
   PubMed Web of Science ®Google Scholar
• Lewis JS, Wiederhold NP, Hakki M, Thompson GR. New Perspectives on antimicrobial agents: isavuconazole. Antimicrob Agents Chemother. 2022;66(9):e0017722.
   PubMed Web of Science ®Google Scholar
• Moore JN, Healy JR, Kraft WK. Pharmacologic and clinical evaluation of posaconazole. Expert Rev Clin Pharmacol. 2015;8(3):321–334.
   PubMed Web of Science ®Google Scholar
• Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013;6:163–174.
   PubMedGoogle Scholar
• Thompson GR, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia. 2010;170(5):291–313.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a Phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–769.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397(10273):499–509.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2–12.
   PubMed Web of Science ®Google Scholar
• Neil M, Ampel M. For Treatment of invasive aspergillosis, posaconazole was noninferior to voriconazole. NEJM Journal Watch. 2021;397(10273):499–509.
   Google Scholar
• Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis. 2003;188(2):305–319.
   PubMed Web of Science ®Google Scholar
• Greer ND. Posaconazole (Noxafil): a new triazole antifungal agent. Proc. 2007;20(2):188–196.
   Google Scholar
• Escribano P, Recio S, Peláez T, Bouza E, Guinea J. Aspergillus fumigatus strains with mutations in the cyp51a gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole. Antimicrob Agents Chemother. 2011;55(5):2460–2462.
   PubMed Web of Science ®Google Scholar
• Won EJ, Joo MY, Lee D, et al. Antifungal susceptibility tests and the cyp51 mutant strains among clinical Aspergillus fumigatus isolates from Korean multicenters. Mycobiology. 2020;48(2):148–152.
   PubMed Web of Science ®Google Scholar
• Snelders E, Karawajczyk A, Schaftenaar G, Verweij PE, Melchers WJG. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother. 2010;54(6):2425–2430.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lu Z, Zhao J, et al. Epidemiology and molecular characterizations of azole resistance in clinical and environmental Aspergillus fumigatus Isolates from China. Antimicrob Agents Chemother. 2016;60(10):5878–5884.
   PubMed Web of Science ®Google Scholar
• Liu M, Zeng R, Zhang L, et al. Multiple cyp51A-based mechanisms identified in azole-resistant isolates of Aspergillus fumigatus from China. Antimicrob Agents Chemother. 2015;9(7):4321–4325.
   Google Scholar
• Mandal SM, Hagiwara D, Sharma C, et al. Uncovering new mutations conferring azole resistance in the Aspergillus fumigatus cyp51A Gene. Front Microbiol. 2020;10:3127.
   PubMed Web of Science ®Google Scholar
• Garcia-Rubio R, Alcazar-Fuoli L, Monteiro MC, et al. Insight into the significance of Aspergillus fumigatus cyp51A polymorphisms. Antimicrob Agents Chemother. 2018;62(6):e00241–18.
   PubMed Web of Science ®Google Scholar
• Morelli KA, Kerkaert JD, Cramer RA. Aspergillus fumigatus biofilms: toward understanding how growth as a multicellular network increases antifungal resistance and disease progression. PLoS Pathog. 2021;17(8):e1009794.
   PubMed Web of Science ®Google Scholar